Molecular Imaging Biomarker Production Facility to Enable Healthcare
Providers Access to PET Technology
HOFFMAN ESTATES, Ill., March 26 /PRNewswire/ -- Siemens Healthcare (http://www.siemens.com/healthcare) today announced its first molecular imaging biomarker production facility in Chennai, India. The new facility will enable the healthcare providers in and around Chennai to access the positron emission tomography-computed tomography (PET-CT) technology to diagnose patients with life-threatening diseases, such as cancer and cardiac and neurological ailments. With this facility, Siemens makes another investment in strengthening critical healthcare infrastructure in the country to elevate the level of available healthcare services.
PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc., operates the largest PET radiopharmacy network with 49 radiopharmacies and distribution centers in the U.S., Korea and the United Kingdom that produce and distribute PET radiopharmaceuticals to hospitals, clinics, and research facilities for PET imaging. The new facility in Chennai will produce and supply the required radiopharmaceuticals to hospitals that have positron emission tomography-computed tomography (PET-CT) facilities, which will help ease the burden of healthcare providers to produce their own radiopharmaceuticals. As a result, the new facility will also help reduce the cost of nuclear medicine and expand its reach to a wider community.
The new facility will feature a Siemens Eclipse(TM) HP cyclotron and
will be Siemens' first molecular imaging biomarker production facility in
India. The Eclipse cyclotron will be deployed to manufacture
fluorodeoxyglucose (FDG), the imaging biomar
|SOURCE Siemens Healthcare|
Copyright©2008 PR Newswire.
All rights reserved